
Please try another search
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Name | Age | Since | Title |
---|---|---|---|
Carol A. Webb | 78 | 2024 | Independent Director |
Joel David Mayersohn | 67 | 2022 | Independent Director |
Eugene Holuka | 66 | 2024 | Independent Director |
Robert J. Smith | 64 | 2024 | Independent Director |
Suren G. Dutia | 82 | 2024 | Independent Director |
Dennis M. McGrath | 68 | 2024 | Independent Director |
Leonard L. Mazur | 80 | 2024 | CEO, President & Executive Chairman |
Myron Z. Holubiak | 78 | 2024 | Secretary & Executive Vice Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review